What We're Reading: Page 88
Industry reads hand-picked by our editors
Feb 21, 2023
-
Associated Press
FDA’s own reputation could be restraining its misinfo fight
-
Stat News
Travere Therapeutics drug approved for rare kidney disease
-
The New York Times
A Fraught New Frontier in Telehealth: Ketamine
-
The Washington Post
Paul Berg, Nobel biochemist who first spliced DNA, dies at 96
Feb 17, 2023
-
BioCentury
Texas abortion ruling could undermine FDA
-
Kaiser Health News
Mark Cuban Has Been Taking On the Drug Industry. But Which One?
-
Fierce Biotech
GSK stands by dumping cell therapies as oligo strategy heats up
-
Bloomberg
Vaccine-Stockpiling Agency Gets a Revamp After Covid Lessons
Feb 16, 2023
-
The Wall Street Journal
Health Startups Offer Diabetes Drugs Like Ozempic for Weight Loss With Little Oversight
-
MIT Technology Review
AI is dreaming up drugs that no one has ever seen. Now we’ve got to see if they work.
-
Nature
How a pioneering diabetes drug offers hope for preventing autoimmune disorders
-
ProPublica
Steak Dinners, Sales Reps and Risky Procedures: Inside the Big Business of Clogged Arteries
Feb 15, 2023
Feb 14, 2023
-
Financial Times
Women’s health ‘missing out’ because of male-dominated investment
-
The Wall Street Journal
Collecting Pharma’s Scraps Can Pay Off for This Biotech
-
The New York Times
Binge Drinking May Be Curbed With a Pill
-
C&EN
In the chemical industry, a tentative journey to ‘point and click’
Feb 13, 2023
Feb 10, 2023
-
NBC News
Fungal infections are becoming more common. Why isn’t there a vaccine?
-
Bloomberg
Advent, CVC Are Among Suitors for €3 Billion Viatris OTC Assets
-
The Wall Street Journal
Layoffs and Shutdowns Hit Biotech Industry in U-Turn
-
In The Pipeline
Molnupiravir Mutations in the Wild
Previous
